Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues $ 0 $ 1,800   $ 1,884
Operating expenses:        
Research and development 2,644 3,272 $ 7,971 6,265
General and administrative 3,525 5,316 16,407 14,863
Total operating expenses 6,169 8,588 24,378 21,128
Operating loss (6,169) (6,788) (24,378) (19,244)
Other income (expense):        
Interest expense (35) 0 (66)  
Interest income 23 40 163 111
Loss on sale of debt securities (98) 0 (98) 0
Royalty income 0 2   7
Total other income (expense) (110) 42 (1) 118
Consolidated net loss from continuing operations (6,279) (6,746) (24,379) (19,126)
Net loss attributable to noncontrolling interest 0 0   1
Net loss attributable to iBio, Inc. from continuing operations (6,279) (6,746) (24,379) (19,125)
Preferred stock dividends - iBio CDMO Tracking Stock 0 0 0 (88)
Net loss available to iBio, Inc. stockholders from continuing operations (6,279) (6,746) (24,379) (19,213)
Loss from discontinued operations (1,015) (5,644) (34,598) (14,124)
Net loss available to iBio, Inc. stockholders (7,294) (12,390) (58,977) (33,337)
Comprehensive loss:        
Consolidated net loss (7,294) (12,390) (58,977) (33,250)
Other comprehensive income - unrealized gain (loss) on debt securities 134 (103) 180 (131)
Other comprehensive income - foreign currency adjustment 33 0 33  
Comprehensive loss $ (7,127) $ (12,493) $ (58,764) $ (33,381)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.47) $ (0.77) $ (2.30) $ (2.20)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.47) (0.77) (2.30) (2.20)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (0.08) (0.65) (3.27) (1.62)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (0.08) (0.65) (3.27) (1.62)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (0.55) (1.42) (5.57) (3.82)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (0.55) $ (1.42) $ (5.57) $ (3.82)
Weighted-average common shares outstanding - basic 13,184 8,719 10,592 8,719
Weighted-average common shares outstanding - diluted 13,184 8,719 10,592 8,719